Circulating biomarkers of tissue remodelling in pulmonary hypertension

References

• Ali O, Wharton J, Gibbs JS, Howard L, Wilkins MR. (2007). Emerging therapies for pulmonary arterial hypertension. Expert Opin Investig Drugs 16:803–18.
   PubMed Web of Science ®Google Scholar
• Asosingh K, Aldred MA, Vasanji A, Drazba J, Sharp J, Farver C, Comhair SA, Xu W, Licina L, Huang L, Anand-Apte B, Yoder MC, Tuder RM, Erzurum SC. (2008). Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 172:615–27.
   PubMedGoogle Scholar
• ATS. (2002). Statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–17.
   PubMed Web of Science ®Google Scholar
• Benza RL, Park MH, Keogh A, Girgis RE. (2007). Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant 26:437–46.
   PubMed Web of Science ®Google Scholar
• Christman B, McPherson C, Newman J, King G, Bernard G, Groves B, Loyd J. (1992). An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70–5.
   PubMed Web of Science ®Google Scholar
• Collins SP, Ronan-Bentle S, Storrow AB. (2003). Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnea. Ann Emerg Med 41:532–45.
   PubMed Web of Science ®Google Scholar
• Cowan KN, Jones PL, Rabinovitch M. (2000). Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105:21–34.
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. (1991). Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343–9.
   PubMed Web of Science ®Google Scholar
• Douglas PS, Khandheria B, Stainback RF, Weissman NJ, Brindis RG, Patel MR, Alpert JS, Fitzgerald D, Heidenreich P, Martin ET, Messer JV, Miller AB, Picard MH, Raggi P, Reed KD, Rumsfeld JS, Steimle AE, Tonkovic R, Vijayaraghavan K, Yeon SB, Hendel RC, Peterson E, Wolk MJ, Allen JM. (2007). ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol 50:187–204.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Hoeper MM. (2008). Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 31:407–15.
   PubMed Web of Science ®Google Scholar
• Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, Szturmowicz M. (2006). Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129:1313–21.
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. (2009). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34:1219–63.
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Olschewski H. (2008). Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31:891–901.
   PubMed Web of Science ®Google Scholar
• Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. (1996). Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271:30375–80.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. (2005). Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26:858–63.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Pletz MW, Golpon H, Welte T. (2007). Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 29:944–50.
   PubMedGoogle Scholar
• Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. (2001). Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 81:1015–24.
   Google Scholar
• Jones FS, Jones PL. (2002). The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 218:235–59.
   Google Scholar
• Kawut SM, Horn EM, Berekashvili KK, Garofano RP, Goldsmith RL, Widlitz AC, Rosenzweig EB, Kerstein D, Barst RJ. (2005). New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 95:199–203.
   PubMed Web of Science ®Google Scholar
• Kramer F, Sandner P, Klein M, Krahn T. (2008). Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat. Biomarkers 13:270–81.
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J. (2004). Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 43:764–70.
   PubMed Web of Science ®Google Scholar
• Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, Korfer R, Klein M, Krahn T, Kruska L, El Banayosy A, Kramer F. (2008). Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 27:589–96.
   PubMed Web of Science ®Google Scholar
• Patel MI, Melrose J, Ghosh P, Appleberg M. Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. J Vasc Surg. 1996;24(1):82–92.
   PubMedGoogle Scholar
• Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. (2004). Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 44:1609–18.
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, Seeger W, Ghofrani HA. (2006). Sildenafil treatment for portopulmonary hypertension. Eur Respir J 28:563–7.
   PubMed Web of Science ®Google Scholar
• Rubin LJ. (1997). Primary pulmonary hypertension. N Engl J Med 336:111–17.
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W. (2005). Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172:358–63.
   PubMed Web of Science ®Google Scholar
• Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A. (2000). TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 279:L562–74.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. (2004). Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(12 Suppl. S):5S–12S.
   Google Scholar
• Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau Ge. (2002). Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40:780–8.
   PubMed Web of Science ®Google Scholar
• Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F, Peyrard S, Agnoletti G, Vouhe PR, Bonnet D, Levy M. (2009). Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 119:374–81.
   PubMed Web of Science ®Google Scholar
• Stroud RE, Deschamps AM, Lowry AS, Hardin AE, Mukherjee R, Lindsey ML, Ramamoorthy S, Zile MR, Spencer WH, Spinale FG. (2005). Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail 11:124–30.
   PubMedGoogle Scholar
• Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, Sheares KK, Hughes R, Morrell NW, Pepke-Zaba J. (2008). Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 134:229–36.
   PubMed Web of Science ®Google Scholar
• Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. (2005). Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 167:71–80.
   PubMed Web of Science ®Google Scholar
• Wagenvoort CA. (1981). Grading of pulmonary vascular lesions–a reappraisal. Histopathology 5:595–8.
   PubMedGoogle Scholar
• Warwick G, Thomas PS, Yates DH. (2008). Biomarkers in pulmonary hypertension. Eur Respir J 32:503–12.
   PubMed Web of Science ®Google Scholar
• Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R. (2002). Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106:319–24.
   PubMed Web of Science ®Google Scholar